Retinoic acid may increase the risk of bone marrow transplant nephropathy.
Bone marrow transplant nephropathy (BMTN) classically presents more than 100 days after transplantation as an acute nephritis with hypertension, azotaemia and anemia that usually results in end stage renal failure (ESRF). The risk of developing BMTN may be greater with the use of more intensive chemotherapy and higher total body and tumor bed irradiation. Cis-retinoic acid (RA) may further increase the risk of developing BMTN. Here, we report the cases of two children who developed typical clinical and biochemical features of BMTN. They were both treated for stage IV neuroblastoma with chemotherapy, bone marrow transplant (BMT) conditioning that included total body irradiation and RA therapy after BMT, although the patient in case 1 had established renal insufficiency prior to the commencement of RA. Renal biopsy of these children showed classical BMTN histology, and the renal manifestations progressed quickly; the patient in case 1 became dialysis dependent by 1 year post-bone marrow transplant. Recently, RA has been added to the post-BMT therapy in children with stage IV neuroblastoma. The occurrence of BMTN in two children treated with RA in our unit is unlikely to be coincidental. Although RA has been shown to confer a significant survival advantage in this disease, animal studies and a previous case report have suggested it could increase the toxic effects of chemotherapy and renal irradiation. It is likely that RA contributed to the deterioration in renal function in these patients.
Haysom
Leigh
L
Department of Nephrology, Sydney Children's Hospital, Randwick, N.S.W., Australia.
Ziegler
David S
DS
Cohn
Richard J
RJ
Rosenberg
Andrew R
AR
Carroll
Susan L
SL
Kainer
Gad
G
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007668:Kidney / Q000473:pathology; D007674:Kidney Diseases / Q000209:etiology* / Q000473:pathology; D008297:Male; D009367:Neoplasm Staging; D009447:Neuroblastoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D011182:Postoperative Care; D013237:Stereoisomerism; D014212:Tretinoin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D014212:Tretinoin
Int J Radiat Oncol Biol Phys. 1988 Jul;15(1):99-104
2968967
J Clin Oncol. 1995 Nov;13(11):2789-95
7595740
Radiology. 1978 Aug;128(2):491-5
663265
Int J Radiat Oncol Biol Phys. 1987 May;13(5):765-72
3106272
Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):1165-73
12419445
Kidney Int. 1999 Aug;56(2):486-93
10432387
Bone Marrow Transplant. 2001 Feb;27(4):451-6
11313676
Acta Radiol Oncol. 1981;20(1):5-8
6264743
Radiat Res. 2002 Feb;157(2):199-203
11835684
Lancet. 1990 Oct 6;336(8719):850-4
1976883
J Lab Clin Med. 1999 Sep;134(3):283-91
10482314
Blood. 1988 Aug;72(2):451-5
3042040
Clin Nephrol. 1978 Aug;10(2):74-8
699403
Cancer Lett. 2003 Jul 18;197(1-2):185-92
12880980
Bone Marrow Transplant. 1997 Apr;19(7):729-35
9156251
Am J Med. 1976 Jan;60(1):127-37
1251842
J Clin Oncol. 1994 Dec;12(12):2607-13
7527454
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1249-56
7713786
Pediatr Nephrol. 1999 Nov;13(9):755-8
10603114
Int J Radiat Oncol Biol Phys. 1994 Mar 1;28(4):883-9
8138441
N Engl J Med. 1990 Feb 15;322(7):417-21
2300104
Phys Med Biol. 1996 Nov;41(11):2307-26
8938028
J Lab Clin Med. 1994 Dec;124(6):761-5
7798787
N Engl J Med. 1999 Oct 14;341(16):1165-73
10519894
Curr Pharm Des. 2003;9(9):737-49
12570791
Bone Marrow Transplant. 2002 Jan;29(2):129-36
11850707
Nephron. 1993;64(4):626-35
8366991
Kidney Int. 1989 Jun;35(6):1336-44
2671466
Bone Marrow Transplant. 1991 May;7(5):383-8
2070148
Arch Physiol Biochem. 1996;104(2):200-6
8818205